In Brief: Neoprobe Neoprobe 1000 study
This article was originally published in The Gray Sheet
Executive Summary
Neoprobe Neoprobe 1000 study: Gamma radiation detecting device employed in a lymphatic breast cancer mapping study by John Albertini, MD, University of South Florida, et al. published in the Dec. 11 Journal of the American Medical Association. The study of 62 patients with newly diagnosed invasive breast cancers found that lymphatic mapping was possible and that histologic characterization of the first lymph node to the primary tumor predicts characteristics of the remaining lymph nodes. "Lymphatic mapping and selective lymphadenectomy could lead to more conservative surgical treatment of women with breast cancer," Albertini et al. conclude. The Neoprobe 1000 was 510(k) cleared in December 1986 for radiation detection, and is used in conjunction with the firm's RIGSCAN CR49 radioimmuno-guided surgery system. The company plans to submit a biologic licensing application for detection of metastatic colorectal cancer ("The Gray Sheet" Oct. 21, p. 9)...